Astellas Pharma Inc. (ALPMY) Financials
ALPMY Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 22.4 billion | 10.9 billion |
| Dec. 31, 2025 | 23.0 billion | 11.7 billion |
| Sept. 30, 2025 | 23.7 billion | 12.6 billion |
| June 30, 2025 | 23.2 billion | 12.9 billion |
ALPMY Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | 1.2 billion | ? |
| Dec. 31, 2025 | 381.7 million | ? |
| Sept. 30, 2025 | 1.5 billion | ? |
| June 30, 2025 | 292.3 million | ? |
ALPMY Net Income
| Date | Net Income |
|---|---|
| March 31, 2026 | 362.9 million |
| Dec. 31, 2025 | 652.0 million |
| Sept. 30, 2025 | 544.6 million |
| June 30, 2025 | 475.8 million |
ALPMY Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 1.8 billion | 2.0 billion | - |
| Dec. 31, 2025 | 1.6 billion | 2.0 billion | - |
| Sept. 30, 2025 | 2.0 billion | 2.2 billion | - |
| June 30, 2025 | 1.5 billion | 3.9 billion | - |
ALPMY Shares Outstanding
ALPMY Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 103.2 million | -1.4 billion | 1.7 billion | - |
| Dec. 31, 2025 | 97.7 million | 491.3 million | 1.4 billion | - |
| Sept. 30, 2025 | 93.5 million | 492.2 million | 1.4 billion | - |
| June 30, 2025 | 89.1 million | 498.6 million | 1.4 billion | - |
ALPMY Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 4.1 billion | 1.2 billion |
| Dec. 31, 2025 | 3.7 billion | 969.1 million |
| Sept. 30, 2025 | 3.6 billion | 950.4 million |
| June 30, 2025 | 3.5 billion | 659.4 million |
ALPMY
Price: $13.23
Dividend Yield: 3.12%
Forward Dividend Yield: 6.11%
Dividend Per Share: 0.83 USD
Earnings Per Share: 1.02 USD
P/E Ratio: 13.70
Exchange: PNK
Sector: Healthcare
Industry: Drug Manufacturers - General
Market Capitalization: 25.2 billion
Average Dividend Frequency: 3
Years Paying Dividends: 18
DGR3: 7.50%
DGR5: 9.03%
DGR10: 6.35%